The limited changes in GFAP levels following nusinersen treatment and the lack of correlation with motor function improvements suggest that glial activation, though potentially involved in SMA pathology, may not be a primary driver of disease progression or treatment response [48,51]. Here, GFAP is linked to proximal spinal muscular atrophy.